Skip to Main Content

Author Details

Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
2010
31
18
PMIDPaper TitleJournal TitlePublished Year
36799863Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer.Cancer Res2023
37348462Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics.Cell Syst2023
36799863Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer.Cancer Res2023
37356470Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.Cancer Lett2023
37348462Positional influence on cellular transcriptional identity revealed through spatially segmented single-cell transcriptomics.Cell Syst2023
37356470Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.Cancer Lett2023
36012586CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.Int J Mol Sci2022
36306264RAS oncogene signal strength regulates matrisomal gene expression and tumorigenicity of mouse keratinocytes.Carcinogenesis2022
36012586CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.Int J Mol Sci2022
35863434The oxidoreductase CLIC4 is required to maintain mitochondrial function and resistance to exogenous oxidants in breast cancer cells.J Biol Chem2022
36306264RAS oncogene signal strength regulates matrisomal gene expression and tumorigenicity of mouse keratinocytes.Carcinogenesis2022
35863434The oxidoreductase CLIC4 is required to maintain mitochondrial function and resistance to exogenous oxidants in breast cancer cells.J Biol Chem2022
32284588Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.Nat Med2020
31949145Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis.Nat Commun2020
32284588Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.Nat Med2020
32747423Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.Mol Cancer Ther2020
33066043A Small Molecule Stabilizer of the MYC G4-Quadruplex Induces Endoplasmic Reticulum Stress, Senescence and Pyroptosis in Multiple Myeloma.Cancers (Basel)2020
31949145Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis.Nat Commun2020
33066043A Small Molecule Stabilizer of the MYC G4-Quadruplex Induces Endoplasmic Reticulum Stress, Senescence and Pyroptosis in Multiple Myeloma.Cancers (Basel)2020
32747423Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.Mol Cancer Ther2020
31164412T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis.Mol Cancer Res2019
31748226Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.Sci Transl Med2019
31921386Head and neck squamous cancer progression is marked by CLIC4 attenuation in tumor epithelium and reciprocal stromal upregulation of miR-142-3p, a novel post-transcriptional regulator of <i>CLIC4</i>.Oncotarget2019
31164412T-Cell Deletion of MyD88 Connects IL17 and IκBζ to RAS Oncogenesis.Mol Cancer Res2019
31748226Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.Sci Transl Med2019
31921386Head and neck squamous cancer progression is marked by CLIC4 attenuation in tumor epithelium and reciprocal stromal upregulation of miR-142-3p, a novel post-transcriptional regulator of <i>CLIC4</i>.Oncotarget2019
30315240Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex.Nat Commun2018
30315240Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex.Nat Commun2018
25546487An in vitro priming step increases the expression of numerous epidermal growth and migration mediators in a tissue-engineering construct.J Tissue Eng Regen Med2017
28522584Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.Mol Cancer Ther2017
25546487An in vitro priming step increases the expression of numerous epidermal growth and migration mediators in a tissue-engineering construct.J Tissue Eng Regen Med2017
28522584Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.Mol Cancer Ther2017
27330189MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.Sci Signal2016
27330189MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.Sci Signal2016
26462961Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.ACS Chem Biol2016
26462961Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.ACS Chem Biol2016
24429254TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.Mol Oncol2014
24429254TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.Mol Oncol2014
24890385An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer.Breast Cancer Res2014
24890385An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer.Breast Cancer Res2014
23146662Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.Biochem Pharmacol2013
23146662Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.Biochem Pharmacol2013
21173787Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Pharmacogenomics J2012
22616030Investigation into diagnostic agreement using automated computer-assisted histopathology pattern recognition image analysis.J Pathol Inform2012
22812567Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.Breast Cancer Res2012
21173787Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Pharmacogenomics J2012
21892208GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.Oncogene2012
22812567Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.Breast Cancer Res2012
22616030Investigation into diagnostic agreement using automated computer-assisted histopathology pattern recognition image analysis.J Pathol Inform2012
21892208GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.Oncogene2012
  • 1 - 50 of 62

Recommended Authors

University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 0
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 0
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 1
University of Toronto
Career Start Year 2005
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 1
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2004
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 1
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 0
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 0
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 0
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 1
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
The Ohio State University
Career Start Year 1997
Number of shared co-authors 0
College of Medicine, The Catholic University of Korea
Career Start Year 1996
Number of shared co-authors 0
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 0
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 0
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 0
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 0
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 1

Collaborators

National Cancer Institute, National Institutes of Health
Co-authored papers 7
School of Public Health, Guizhou Medical University
Co-authored papers 7
Center for Cancer Research, National Cancer Institute
Co-authored papers 7
Center for Cancer Research, National Cancer Institute
Co-authored papers 6
Center for Cancer Research, National Cancer Institute
Co-authored papers 5
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
National Center for Advancing Translational Sciences
Co-authored papers 2
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
National Center for Advancing Translational Sciences
Co-authored papers 2
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Centers for Disease Control and Prevention
Co-authored papers 2
The University of Manchester
Co-authored papers 2
National Cancer Institute, National Institutes of Health (NIH)
Co-authored papers 2
Co-authored papers 1
National Institutes of Health, National Center for Advancing Translational Sciences
Co-authored papers 1
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Co-authored papers 1
National Center for Advancing Translational Sciences, National Institutes of Health
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
College of Life Science, Zhejiang University
Co-authored papers 1
Center for Cancer Research, National Institutes of Health
Co-authored papers 1
Co-authored papers 1
Center for Cancer Research, National Cancer Institute
Co-authored papers 1
National Center for Advancing Translational Sciences, National Institutes of Health
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc.
Co-authored papers 1
Vertex Pharmaceuticals
Co-authored papers 1